News April 21, 2026

Brenipatide Might Be Lilly's Most Overlooked Peptide Story After Retatrutide

Retatrutide gets the hype, but Lilly's investigational peptide brenipatide is being studied across alcohol use disorder, major depressive disorder, bipolar disorder, smoking relapse, opioid use disorder, and more. Here is what the official trial record actually shows.

Retatrutide is still the louder name in peptide and GLP-1-adjacent conversations.

That makes sense. It is tied directly to obesity, weight-loss hype, and the “next big thing” instinct that tends to dominate this part of the market.

But if you want the more interesting pipeline story, the one worth quietly watching over the next few years may be brenipatide, also known as LY3537031.

Not because it is available now.

Not because there is some hidden gray-market shortcut.

And not because it is about to become the next retail obesity craze tomorrow.

The interesting part is where Eli Lilly is actually taking it.

The overlooked angle

The simplest reason brenipatide stands out is that Lilly is not only studying it in classic obesity-adjacent territory.

The current trial record shows a much broader development map:

two Phase 3 trials in alcohol use disorder
a Phase 3 trial in major depressive disorder
a Phase 2 trial in bipolar disorder
a Phase 2 trial in adults who quit smoking cigarettes and want to avoid relapse
a Phase 2 trial in opioid use disorder
a Phase 1 renal-impairment study
a Phase 1b study in healthy participants with overweight or obesity

That is a very different posture than treating brenipatide as just another weight-loss contender.

Even before you get into mechanism debates, Lilly’s own study portfolio is telling you something:

This is being explored as a broader craving-, relapse-, mood-, and behavior-adjacent program, not just a body-weight story.

What the official trial record shows

Here is the cleanest current snapshot from the official registries.

Alcohol use disorder: already in Phase 3

Lilly has two separate Phase 3 alcohol-use-disorder studies on the public record:

RENEW-ALC-1 (NCT07219966), a Phase 3 randomized, double-blind study in adults with moderate-to-severe alcohol use disorder
RENEW-ALC-2 (NCT07219953), another Phase 3 randomized, double-blind study in adults with alcohol use disorder

Both studies are listed as starting in October 2025 and both currently show estimated completion in April 2028.

That matters because it moves the brenipatide story out of the purely speculative bucket. This is not an idea on a slide. Lilly already has late-stage alcohol-use-disorder studies running.

The Phase 3 trial designs also make the bet more explicit. The official outcome measures include:

changes in drinking patterns
changes in daily alcohol consumption
changes in alcohol craving

So while retatrutide dominates online attention, brenipatide may be the program that says more about where incretin-style peptide development is going next.

Bipolar disorder: Phase 2

The bipolar-disorder angle is real, but it is important not to overstate it.

The public record shows RENEW-Bipolar-1 (NCT07286175) as a Phase 2 randomized, double-blind study evaluating brenipatide as adjunctive treatment, compared with placebo plus standard of care, in adult participants with bipolar disorder.

The study’s stated purpose is to assess efficacy and safety in delaying worsening or relapse of bipolar symptoms.

That is notable on its own. But it is not a Phase 3 bipolar program yet, and that distinction matters.

Major depressive disorder: another late-stage mood signal

There is also a public registry entry for RENEW-MDD-1 (NCT07412756), a Phase 3 study evaluating brenipatide as adjunctive treatment, compared with placebo plus standard of care, in adult participants with major depressive disorder.

The study is designed around delay to relapse of major depressive symptoms.

That does not prove the program will work.

But it does reinforce the broader point: Lilly is not only exploring brenipatide as a metabolic or obesity-adjacent asset. It is also taking the compound directly into major mood-disorder territory.

Smoking relapse: Phase 2

Another public trial, NCT07223840, is a Phase 2 study in adults who recently quit smoking cigarettes and want to avoid relapse.

The primary endpoint there is carbon-monoxide-confirmed continuous abstinence from cigarette smoking over 24 weeks.

Again, that is not an obesity endpoint.

It is a relapse-prevention endpoint.

Opioid use disorder: Phase 2

Lilly also has RENEW-Op-1 (NCT07420283) in Phase 2, studying brenipatide as adjunctive treatment to buprenorphine, with or without naloxone, in participants with opioid use disorder during early recovery.

The official endpoints include:

percentage of weeks of abstinence from opioid use
achievement of high-abstinence thresholds
overdose occurrence
changes in craving and functioning

That is a very direct signal that Lilly is testing brenipatide in settings where reward, relapse, and compulsive behavior matter.

Early-stage metabolic and PK work is still happening too

The broader development picture includes at least two other official studies worth noting:

NCT07165015, a Phase 1 study evaluating pharmacokinetics and safety of LY3537031 in participants with normal renal function and participants with renal impairment
NCT07476118, a Phase 1b study in healthy participants with overweight or obesity, evaluating pharmacodynamics, safety, tolerability, and pharmacokinetics

That is another clue that the compound is still early enough in some areas that the story should be framed carefully.

This is not a finished product story.

It is a pipeline story.

Why this matters more than the average peptide headline

There are a lot of reasons a compound can get attention online:

because it sounds more powerful than the last one
because an influencer brings it up
because people want to front-run the next approval cycle
because the peptide market loves novelty

Brenipatide is interesting for a different reason.

Its significance is not just that it exists.

Its significance is that Lilly appears to be testing whether an incretin-linked peptide can matter in areas like:

alcohol-use reduction
smoking-relapse prevention
opioid-use recovery support
bipolar-disorder symptom stability

That is a much bigger conceptual bet than “another obesity drug.”

It points toward a broader question:

What if some of the most commercially important peptide stories over the next few years are not just about appetite and body weight, but about craving, reinforcement, relapse, and behavioral control?

That is the part worth watching.

The claim people should be careful with

This is also where online discussion can get sloppy fast.

It is tempting to jump from “Lilly is studying brenipatide in addiction-related conditions” to “we already know exactly how it works in the brain” or “this is obviously the next breakthrough for craving.”

That would be too aggressive.

What the public trial record supports today is simpler:

Lilly is running serious studies in addiction- and psychiatry-adjacent indications
those studies are far enough along in alcohol use disorder to reach Phase 3
but the program is still investigational
and there is still a long distance between an active trial portfolio and an approved product

That distinction matters.

The reality check

Right now, brenipatide is still an investigational Lilly compound.

There is no FDA-approved brenipatide product. There is no normal prescription-market access. And the late-stage alcohol-use-disorder studies currently show estimated completion in April 2028.

So this is not a “how do I get some?” story.

It is a “pay attention to where the pipeline is heading” story.

That is a very different thing.

The practical takeaway

If you only follow peptide hype through the weight-loss lens, it is easy to miss what brenipatide may represent.

Retatrutide gets the clicks because it fits the current moment.

Brenipatide may turn out to matter because it points to the next moment.

Not the “everyone is talking about it on X” moment.

The “major drugmakers are testing incretin-linked peptides across addiction, mood, relapse, and behavior” moment.

That is a bigger story than most peptide content is giving it credit for right now.